May 09, 2017 20:10 pm UTC| Business
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA)...
Codexis Reports Financial Results for the First Quarter of 2017
May 09, 2017 20:10 pm UTC| Business
Product sales increase 49% Highlights include signing second multiyear agreement in the food industry and initiating beta testing of first company-developed enzyme for the molecular diagnostics industry Conference...
May 09, 2017 20:10 pm UTC| Business
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA)...
May 09, 2017 20:10 pm UTC| Business
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA)...
Codexis Reports Financial Results for the First Quarter of 2017
May 09, 2017 20:10 pm UTC| Business
Product sales increase 49% Highlights include signing second multiyear agreement in the food industry and initiating beta testing of first company-developed enzyme for the molecular diagnostics industry Conference...
Codexis Reports Financial Results for the First Quarter of 2017
May 09, 2017 20:09 pm UTC| Business
Product sales increase 49% Highlights include signing second multiyear agreement in the food industry and initiating beta testing of first company-developed enzyme for the molecular diagnostics industry Conference...
Rightside® Announces First Quarter 2017 Financial Results
May 09, 2017 20:09 pm UTC| Business
First Quarter Registry Revenue Grows 20% Over the Prior Year PeriodCompany Repurchases Approximately $3.0 Million in Common Stock Year-to-Date KIRKLAND, Wash., May 09, 2017 -- Rightside Group, Ltd. (Nasdaq:NAME),...